CD47
The 'don't eat me' signal cancer cells show to macrophages. Blocking it looked promising but the lead drug failed.
Magrolimab was discontinued after failed trials in MDS and AML (ENHANCE), with excess deaths. The macrophage checkpoint concept persists with SIRPα-targeted agents and bispecifics with lower haematologic toxicity.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · The 'don't eat me' signal cancer cells show to macrophages. Blocking it looked promising but the lead drug failed.
- 1 · What it is
The 'don't eat me' signal cancer cells show to macrophages. Blocking it looked promising but the lead drug failed.
- 2 · What goes wrong in cancer
Binds SIRPα on macrophages to inhibit phagocytosis; ubiquitous on red cells, causing anaemia.
- 3 · How drugs use it
1 product aims at CD47: antibodies. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
Biology
Binds SIRPα on macrophages to inhibit phagocytosis; ubiquitous on red cells, causing anaemia.
- Broadly on tumour cells
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute myeloid leukaemia | >90% | Surface expression on blasts | Magrolimab discontinued | Wikipedia |
| Diffuse large B-cell lymphoma | >90% | Surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"CD47" OR ABSTRACT:"CD47") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD47, not a curated reading list.